BMY · Bristol-Myers Squibb Co
Price
Snapshot
50 fields · last close| Market Cap | $122.1B |
| P/E | 13.15 |
| Float | 2.04B |
| Beta | 0.19 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 80.1 |
| Price | 58.90 |
| Change | −1.42% |
| Prev Close | 59.75 |
| Open | 61.10 |
| Day Low | 59.54 |
| Day High | 61.43 |
| Avg Vol | 14 |
| Avg $ Vol | $858.3M |
| 52W High | 68.64 |
| 52W Low | 42.52 |
| 52W Pos | 62.7% |
| From High | −14.19% |
| From Low | +38.52% |
| Max DD 1Y | −16.77% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −2.87% |
| SMA 50 | −7.25% |
| SMA 200 | −1.24% |
| RSI (14) | 44.3 |
| Vol 30D | 26.9% |
| Vol 90D | 27.8% |
| 1Y Range | 43–69 |
| Daily bars | 899 |
| Perf Week | +1.07% |
| Perf Month | −4.92% |
| Perf Quarter | −0.68% |
| Perf Half Y | −0.70% |
| Perf Year | +37.01% |
| Perf YTD | +10.18% |
| Prev Day | −1.42% |
| Clavix | B+ |
| Debt / Eq | 2.43 |
| Curr Ratio | 1.26 |
| Int Cover | 20.1× |
| FCF Margin | 26.7% |
| Rev Growth | −0.2% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 6 / 14 |
What BMY does
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM.
It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer.
Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies.
Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer.
The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Clavix risk grade
regraded every trading dayBMY grades B+, 80.1 of 100. Steadiest on Macro Resilience (68), most exposed on News Sentiment (54, mixed). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 6 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| BMY | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.19 | 0.44 |
| Volatilityannualized | 5.0% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −16.8% | — |
| Typical daily movemedian absolute daily change | 0.96% | — |
| Days beyond ±3%of the last 252 sessions | 24 (10%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BMY | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.19 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BMY | |
|---|---|
| 1 week | +1.1% |
| 1 month | −4.9% |
| Year to date | +10.2% |
| 1 year | +37.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BMY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Sep |
| Average score0 most bearish, 100 most bullish | 57 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 8 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 8 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| BMY | |
|---|---|
| Revenue growthyear over year | −0.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGoldman Sachs raised its rating on Bristol Myers Squibb (BMY) shares from "hold" to "strong-buy" in a report issued on Friday. The article provides no price target or reasoning.
BMY pays a 4.2% dividend yield and has raised its payout every year for 17 straight years, but a wave of upcoming patent expirations and $43 billion in debt could squeeze future increases.
Bristol Myers Squibb has raised its dividend every year for 17 straight years, giving it a 4.2% dividend yield. The article warns that upcoming patent expirations on key drugs and $43 billion in debt could limit how fast those dividend increases continue.
Bristol Myers Squibb reported positive Phase 3 results for three late-stage drugs: RYZ101 for a rare digestive-system tumor, admilparant for a lung-scarring disease with no known cause, and ZENBEXUS for a blood cancer that has returned after prior treatment.
Bristol-Myers Squibb's pulmonary fibrosis drug admilparant, which works by blocking a receptor (LPA1) linked to scarring in the lungs, produced mixed results in a recent Phase 3 trial. UBS, an investment bank, says the drug can still succeed commercially despite the uneven data. The article body was cut off, so further details were not available.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc | A- | $168.6B | 38.91 | 0.31 | Compare |
| AZN | AstraZeneca PLC | B+ | $196.9B | 25.12 | 1.27 | Compare |
| MRK | Merck & Co Inc | B+ | $360.1B | 113.48 | 0.12 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| JNJ | Johnson & Johnson | A- | $615.9B | 38.26 | 0.21 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.65B | 14.51 | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.